摘要
慢性阻塞性肺疾病(COPD)是常见的肺部疾病,症多见呼吸困难、慢性咳嗽、气道炎症反应。近年来中医药在治疗呼吸系统疾病方面取得了显著进展,其在调控肺肠黏膜免疫系统方面具有长足的潜力,对COPD的治疗具有重要意义。特别是黏膜淋巴细胞迁移归巢机制介导的肺肠信号转导显示出肺肠密切的关联性,靶向肺肠黏膜免疫系统是治疗肺系疾病新的有效途径。故通过综述肺肠黏膜免疫应答调节机制,以及近年来中医药调控肺肠黏膜免疫系统治疗COPD的研究进展,研究发现中医药可通过拮抗气道和肺部炎症反应干预COPD,通过调节固有淋巴细胞(ILC)、辅助性T细胞17(Th17)免疫应答,修复黏膜屏障,以及通过调节肺肠黏膜淋巴细胞迁移归巢等途径干预COPD。为进一步探索与应用中医药治疗COPD和其他肺系疾病提供参考依据,也为深入的临床开发和机制研究提供基础和方向。
Chronic obstructive pulmonary disease(COPD)is a common lung condition characterized by symptoms such as dyspnea,chronic cough,and airway inflammatory responses.In recent years,traditional Chinese medicine(TCM)has made significant progress in treating respiratory diseases,demonstrating considerable potential in modulating the pulmonary-gut mucosal immune system,which is crucial for COPD treatment.Particularly,pulmonary-gut signal transduction mediated by the mechanisms of mucosal lymphocyte migration and homing highlights the close relationship between the lungs and the gut,suggesting that targeting the pulmonary-gut mucosal immune system is a new effective approach for treating lung diseases.This review discussed the regulatory mechanisms of pulmonary-gut mucosal immune responses and recent research advancements in TCM modulation of this system in COPD treatment.Findings indicate that TCM can intervene in COPD by antagonizing airway and lung inflammatory responses,regulating innate lymphoid cells(ILCs)and T helper 17(Th17)immune responses,repairing the mucosal barrier,and adjusting the migration and homing of pulmonary-gut mucosal lymphocytes.This research provides a reference for further exploration and application of TCM in treating COPD and other lung diseases,as well as foundational insights and directions for in-depth clinical development and mechanistic studies.
作者
王卫
朱邵晴
张元斌
王曼
褚琳
杨欢
郁红礼
WANG Wei;ZHU Shaoqing;ZHANG Yuanbin;WANG Man;CHU Lin;YANG Huan;YU Hongli(School of Pharmacy,Jiangsu University,Zhenjiang 212013,China;School of Medicine and Chemical Engineering,Zhenjiang College,Zhenjiang 212028,China;Zhenjiang Key Laboratory of Functional Chemistry,Zhenjiang 212028,China;Department of Pharmacy,The First Affiliated Hospital of Ningbo University,Ningbo 315010,China;Zhenjiang First People′s Hospital,Jiangsu University,Zhenjiang 212000,China;School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing 210023,China)
出处
《世界中医药》
北大核心
2024年第20期3203-3210,共8页
World Chinese Medicine
基金
国家自然科学基金面上项目(82374143)
江苏省自然科学基金项目(BK20200907)
江苏省高校自然科学基金面上项目(22KJB360019)
镇江市重点研发计划社会发展项目(SH2021047)
江苏大学高等教育教改研究课题项目(2023JGYB064)。
关键词
慢性阻塞性肺疾病
黏膜免疫系统
中药
活性成分
天然淋巴细胞
辅助性T细胞17
归巢
炎症反应
Chronic obstructive pulmonary disease
Mucosal immune system
Chinese medicine
Active ingredients
Innate lymphoid cells
Helper T cell 17
Homing
Inflammatory response
